MARKET

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ
1.040
-0.030
-2.80%
After Hours: 1.020 -0.02 -1.88% 19:17 07/24 EDT
OPEN
1.060
PREV CLOSE
1.070
HIGH
1.070
LOW
1.030
VOLUME
85.11K
TURNOVER
--
52 WEEK HIGH
4.190
52 WEEK LOW
0.8127
MARKET CAP
12.08M
P/E (TTM)
-0.6994
1D
5D
1M
3M
1Y
5Y
1D
Phio Pharma corrects date for Renmark virtual non-deal roadshow presentation
PUBT · 3d ago
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Newsfile · 3d ago
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Newsfile · 3d ago
Phio Pharmaceuticals adds dermatology expert to board
TipRanks · 4d ago
Phio Pharmaceuticals names dermatologist R. Todd Plott to board
PUBT · 4d ago
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
Newsfile · 4d ago
Weekly Report: what happened at PHIO last week (0713-0717)?
Weekly Report · 5d ago
Phio Secures Additional Patent Protection In US, Canada, Japan For INTASYL Compounds
NASDAQ · 07/17 15:17
More
About PHIO
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

Webull offers Phio Pharmaceuticals Corp stock information, including NASDAQ: PHIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PHIO stock methods without spending real money on the virtual paper trading platform.